Announcements Trials
Browse Landscape

Phase

Phase NA 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 12Breast 8Thoracic 5Gynecologic 5Other solid neoplasm 3Other hematologic neoplasm 3Lymphoid 2Tumor-Agnostic 1Plasma cell 1Other 1Genitourinary 1

Conditions

Neoplasms 1

Interventions

pembrolizumab 56Specimen Handling 28Biopsy 27Magnetic Resonance Spectroscopy 26Paclitaxel 22Blood Specimen Collection 21Nivolumab 20atezolizumab 18Standard of Care 18Carboplatin 18Surveys and Questionnaires 17Bevacizumab 17Oxaliplatin 13Fluorouracil 13Cisplatin 13Radiotherapy 12Radiosurgery 12Cyclophosphamide 12Pemetrexed 11Leucovorin 11Irinotecan 10Gemcitabine 10Docetaxel 10Capecitabine 10trastuzumab deruxtecan 8olaparib 8Taxes 8Ipilimumab 8durvalumab 7Trastuzumab 7

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Patient Navigation × Tumor-Agnostic × 1 year × Clear all
NCT04234646 2026-06-02

Patient Navigation 2.0

Northwestern University

Phase NA Completed
600 enrolled
Tumor-Agnostic

Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡